NCT04916756View on ClinicalTrials.gov

A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 16, 2020

Primary Completion Date

December 24, 2020

Study Completion Date

March 25, 2021

Conditions
Sjogren's Syndrome
Interventions
DRUG

Baricitinib 2 MG

baricitinib 2mg per day for 24 weeks

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT04916756 - A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome Patients | Biotech Hunter | Biotech Hunter